Dri Healthcare Trust (DHTRF) Financiero

DRI Healthcare Trust is an unincorporated open-ended company. The firm's portfolio consists of 29 royalty streams on 23 products that treat conditions in a number of therapeutic areas, including oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, as well as lysosomal storage disorders (LSD) and immunology. Its Royalty Assets include Ekterly, Eylea I, Eylea II, Natpara, Omidria, Oracea, Orserdu I, Orserdu II, Rydapt, Spinraza, Vonjo I, Vonjo II, Xolair, Zejula, Zytiga, and others. The Ekterly is an oral on-demand therapy for treating attacks associated with Hereditary Angioedema (HAE). The Eylea I is a vascular endothelial growth factor inhibitor initially indicated for the treatment of neovascular wet age-related macular degeneration. Natpara is indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.